Interestingly, a more recent study has implicated a highly-conserved nuclear protein called high-mobility group box 1 (HMGB1) in APL DS pathogenesis via the MEK/ERK signaling pathway and has suggested that HMGB1 may be a possible future target in the treatment of DS (119). This evidence concerns the gene HMGB1 and acute promyelocytic leukemia.